CCM
KPTI icon

Catalio Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Catalio Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5M Buy
897,709
+754,725
+528% +$5.75M 1.04% 29
2025
Q4 		$1.05M Hold
142,984
– – 0.19% 41
2025
Q3 		$935K Sell
142,984
-3,029
-2% -$16.3K 0.17% 36
2025
Q2 		$629K Sell
146,013
-9,609
-6% -$47.1K 0.13% 35
2025
Q1 		$582K Sell
155,622
-3
-0% -$26 0.14% 33
2024
Q4 		$1.58M Buy
+155,625
New +$1.88M 0.35% 28

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Catalio Capital Management's KPTI Position: Q1 2026 in Review

Catalio Capital Management increased its Karyopharm Therapeutics (KPTI) stake by 528% in Q1 2026, buying an estimated $5.75M and bringing the position to 897,709 shares worth $5M. The position accounts for 1.04% of the portfolio, ranked #29.

Catalio Capital Management first reported a position in KPTI in Q4 2024 and has held it in 6 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Catalio Capital Management held 897,709 shares of Karyopharm Therapeutics worth $5M as of Q1 2026.
  • Catalio Capital Management bought 754,725 Karyopharm Therapeutics shares in Q1 2026, an estimated $5.75M.
  • Karyopharm Therapeutics made up 1.04% of Catalio Capital Management's portfolio in Q1 2026, its #29 holding.
  • Catalio Capital Management first reported a position in Karyopharm Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.